Nicandro JP, Tennis P, Bennett L, Hollis K, Shin P, Chuang E, Andrews E. Disability or restriction of daily activities is the most common indicator of disease severity in female patients with severe IBS-D: an analysis of the alosetron patient survey. Poster presented at the 2010 American College of Gastroenterology (ACG) Annual Scientific Meeting; October 2010. San Antonio, TX. [abstract] Am J Gastroenterol. 2010 Oct; 105(Suppl. 1):S410.
Hollis KA, Tennis P, Nicandro J, Chuang E, Sweeney CT, Bennett L, Andrews E. Temporal trends in compliance with the alosetron risk management program. Poster presented at the 26th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2010. Brighton, United Kingdom.
Nicandro J, Tennis P, Shin P, Hickman P, Bennett L, Hollis KA, Andrews E. One-year treatment continuation with alosetron is high irrespective of ibs-d severity criteria. Poster presented at the 2010 Digestive Disease Week; April 30, 2010.
Miller DP, Bennett L, Hollis KA, Tennis P, Cook SF, Andrews E. A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Aliment Pharmacol Ther. 2006 Sep 1;24(5):869-78.
Andrews EB, Hollis KA, Miller D, Tennis P, Bennett L, Ameen VZ, Heath A, McSorley D, Cook SF. A patient follow-up survey program for lotronex (Alosetron HCL): accessing compliance with the risk management program. Poster presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux.